Impact of circulating microRNA test (miRNA-371a-3p) on appropriateness of treatment and cost outcomes in patients with Stage I non-seminomatous germ cell tumours.
Aditya BagrodiaAnna SavelyevaJohn T LafinRyan W SpeirGregory T ChesnutAnne Lindsay FrazierSolomon L WolduVitaly MargulisMatthew Jonathan MurrayJames F AmatrudaYair LotanPublished in: BJU international (2020)
A miRNA-based approach may potentially select patients with Stage I NSGCT for correct treatment in a cost-effective manner. Identification of residual teratoma-only remains an issue. Prospective studies are necessary to validate these findings.